Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Greenwich Lifesciences

Tenet Healthcare

Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer. Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases.

Why Greenwich LifeSciences, Immutep And Tenet Are Trading Higher Today

Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.

Immutep shares soar 190% on positive results in trial of breast cancer treatment

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to report encouraging first Overall Survival (OS) follow up data from its ongoing Phase IIb AIPAC study evaluating Immutep's lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy (“efti group”) in comparison to a combination of placebo and paclitaxel chemotherapy (“comparator group”) in patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). These data were selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually this week from Texas, USA.

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial.

Immutep Announces Expansion of TACTI-002 Collaboration Trial

﻿Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully completed a A$29.6 million a private placement of ordinary shares to professional and institutional investors (Placement).

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release                                                                                                                    

Immutep's Phase II TACTI-002 Study Reports Encouraging Data at SITC

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of eftilagimod alpha (“efti”) has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting, which is taking place as a virtual event from 9-14 November, US Eastern Standard Time (US EST).

Immutep's TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with LabCorp that will support the development of immuno-oncology products or services.

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomized Phase II clinical trial evaluating its lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalized patients with COVID-19. The necessary approvals from the Czech Republic's State Institute for Drug Control (SUKL- competent authority) and ethics committee have now been obtained, enabling the recruitment of patients to commence immediately. Initial interim results are expected to be reported from early 2021.

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today provided a business update for the quarter ended September 30, 2020, including for the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activity of its new and existing partners.

Immutep Activities Report for the First Quarter of Fiscal Year 2021

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office.

Immutep Granted European Patent for IMP761

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that interim Overall Survival (OS) results from its Phase IIb AIPAC study has been selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually in December 2020 from Texas, USA.

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

SYDNEY, Australia, Sept.  18, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date of 21 August 2020.

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

SYDNEY, Australia, Sept.  18, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 on 17 September 2020, CEST (poster ID number 1032P) by trial investigator at Institute of Clinical Cancer Research, Krankenhaus Nordwest (IKF), PD Dr. Thorsten Götze.

Immutep Reports Improving Results from INSIGHT-004 Trial

SYDNEY, Australia, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,427 grant under the ARC‘s Linkage Project scheme to support their research collaboration into Lymphocyte Activation Gene-3 (LAG-3) for a further three years.

Immutep and Monash University Receive Grant Funding for LAG-3 Project

SYDNEY, Australia, Aug.  26, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce new data is scheduled to be presented in four poster presentations at the ESMO Virtual Congress 2020 which is being held from 19 to 21 September 2020, Central European Summer Time (CEST).

New Data From Immutep’s efti to be Presented at ESMO

SYDNEY, Australia, Aug.  18, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 1 of Part B of its TACTI-002 Phase II study, completing recruitment of stage 1 of Part B.

Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study

SYDNEY, Australia, July  15, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.

Immutep Announces United States Patent Grant for IMP701 Antibody

SYDNEY, Australia, June  29, 2020  (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part A (1st line NSCLC) of its TACTI-002 Phase II study, completing recruitment for Part A.

Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study

SYDNEY, Australia, June  22, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2019 fiscal year, mainly related to the Company’s TACTI-mel  and TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Immutep receives A$1,437,826 R&D Tax Incentive

Immutep Announces Improving Data from the Phase II TACTI-002 Study

SYDNEY, Australia, June  01, 2020  (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“IMP321” or “efti”) with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. The data was reported in a short talk poster presentation by Dr Thorsten O. Goetze, trial investigator, at the virtual event for the 2020 American Society of Clinical Oncology’s (ASCO) Annual Meeting. The poster presentation from Dr Goetze is available on the company’s website (click here).  

Immutep Reports First Results from INSIGHT-004 Study

SYDNEY, Australia, May  29, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~ US$2,407,817) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Immutep Receives US$2.4 Million R&D Tax Incentive from French Government

SYDNEY, Australia, April  22, 2020  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical trial. This completes enrollment for the study.

News for Immutep Ltd Stock (IMMP)